Drugs & Therapy Perspectives

, Volume 17, Issue 2, pp 4–10 | Cite as

Individualised therapy for migraine possible as the triptan family expands

New drugs and disease management


Migraine Sumatriptan Zolmitriptan Actinic Keratosis Ergotamine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kaube H, May A, Diener HC et al. Sumatriptan misuse in daily chronic headache. BMJ 1994; 308: 1573PubMedCrossRefGoogle Scholar
  2. 2.
    Limmroth V, Kazarawa S, Fritsche G, et al. Headache after frequent use of new 5-HT agonists zolmitriptan and naratriptan. Lancet 1999; 353: 378PubMedCrossRefGoogle Scholar
  3. 3.
    Katsarava Z, Fritsche G, Diener HC, et al. Drug-induced headache (DIH) following the use of different triptans [abstract]. Cephalagia 2000; 20: 293Google Scholar


  1. 1.
    Tepper SJ, Rapoport AM. The triptans: a summary. CNS Drugs 1999 Nov; 12(5): 403–17CrossRefGoogle Scholar
  2. 2.
    British National Formulary. No. 39. London: The Pharmaceutical Press, 2000 Mar: 219-20, 596-7Google Scholar
  3. 3.
    Drug Topics Red Book. Montvale (NJ): Medical Economics Company, 2000Google Scholar
  4. 4.
    Edvinsson L, Goadsby PJ. Neuropeptides in headache. Eur J Neurol 1998; 5: 329–41CrossRefGoogle Scholar
  5. 5.
    International Headache Society Committee on Clinical Trials in Migraine. Guidelines for controlled trials of drugs in migraine. 1st ed. Cephalalgia 1991; 11: 1–12CrossRefGoogle Scholar
  6. 6.
    Gobel H, Baar H, Beikufner HD, et al. Practicability and acceptance of subcutaneous self-administration of the selective serotonin agonist sumatriptan. Headache 1998; 38: 267–9PubMedCrossRefGoogle Scholar
  7. 7.
    Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000 Dec; 60(6): 1259–87PubMedCrossRefGoogle Scholar
  8. 8.
    Spencer CM, Gunasekara NS, Hills C. Zolmitriptan: a review of its use in migraine. Drugs 1999 Aug; 58(2): 347–74PubMedCrossRefGoogle Scholar
  9. 9.
    Sheftell F, O’Quinn S, Watson C, et al. Low headache recurrence with naratriptan: clinical parameters related to recurrence. Headache 2000 Feb; 40(2): 103–10CrossRefGoogle Scholar
  10. 10.
    Dooley M, Faulds D. Rizatriptan: a review of its efficacy in the management of migraine. Drugs 1999 Oct; 58(4): 699–723CrossRefGoogle Scholar
  11. 11.
    New Ethicals Compendium. 7th edition. Auckland: Adis International Limited, 2000: 1110-2Google Scholar
  12. 12.
    Goadsby PJ, Ferrari MD, Eletriptan Steering Committee. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Neurology 2000 Jan 11; 54(1): 156–63PubMedCrossRefGoogle Scholar
  13. 13.
    Holm KJ, Spencer CM. Almotriptan. CNS Drugs 1999 Feb; 11(2): 159–64CrossRefGoogle Scholar
  14. 14.
    Easthope S, Goa KL. Frovatriptan. CNS Drugs. In pressGoogle Scholar
  15. 15.
    Bardsley-Eliot A, Noble S. Eletriptan. CNS Drugs 1999 Oct; 12(4): 325–33CrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Personalised recommendations